Geode Capital Management LLC Boosts Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Geode Capital Management LLC increased its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 14.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,043,864 shares of the company’s stock after purchasing an additional 129,600 shares during the period. Geode Capital Management LLC owned approximately 1.98% of Zevra Therapeutics worth $7,246,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ZVRA. FMR LLC raised its position in shares of Zevra Therapeutics by 282,687.5% during the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after buying an additional 2,312,384 shares in the last quarter. State Street Corp increased its stake in Zevra Therapeutics by 7.4% during the third quarter. State Street Corp now owns 772,825 shares of the company’s stock worth $5,363,000 after acquiring an additional 52,966 shares during the last quarter. Stonepine Capital Management LLC purchased a new stake in Zevra Therapeutics during the third quarter valued at approximately $4,858,000. Vestal Point Capital LP bought a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $3,644,000. Finally, Retirement Planning Co of New England Inc. boosted its holdings in shares of Zevra Therapeutics by 6.5% in the 2nd quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock worth $2,246,000 after purchasing an additional 28,107 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Price Performance

Shares of ZVRA stock opened at $8.76 on Friday. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a fifty day simple moving average of $8.75 and a two-hundred day simple moving average of $7.45. The stock has a market capitalization of $467.57 million, a price-to-earnings ratio of -4.45 and a beta of 1.97.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. During the same period last year, the company earned ($0.40) earnings per share. On average, analysts predict that Zevra Therapeutics, Inc. will post -1.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ZVRA shares. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Roth Mkm increased their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Finally, Guggenheim started coverage on Zevra Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $20.00 target price on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.